Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine + cytarabine for elderly AML and high-risk MDS with high early mortality risk
2015-004896-60Phase 2Active
- Sponsor
- Leiden University Medical Center
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of decitabine and cytarabine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Leiden University Medical Center. Primary endpoint: Day 30 mortality. Started Nov 2015; status: active.
02
Drugs
decitabinecytarabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2015-004896-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004896-60.